

4th Cuneo City ImmunoTherapy Conference (CCITC)

Immunotherapy in Hematological Malignancies 2024

October 10-12, 2024

Spazio Incontri Fondazione CRC
CUNEO



Organized by Prof. Massimo Massaia, SC Ematologia AO S.Croce e Carle, Cuneo - Italy and
Centro Interdipartimentale di Biotecnologie Molecolari "Guido Tarone" (MBC), Torino - Italy



SIE – Società Italiana di Ematologia



**UNIVERSITÀ
DI TORINO**

Immunotherapy in Hematological Malignancies 2024

October 10-11-12, 2024

CIRINO	BOTTA	Palermo, Italy
BENEDETTO	BRUNO	Torino, Italy
CARMELO	CARLO-STELLA	Rozzano-MI, Italy
GIULIA	CASORATI	Milano, Italy
CLAUDIA	CASTELLINO	Cuneo, Italy
VINCENZO	CERULLO	Helsinki, Finland
ROBERTO	CHIARLE	Boston, USA; Milano-Torino, Italy
FABIO	CICERI	Milano, Italy
DANIELA	CILLONI	Torino, Italy
PAOLO	CORRADINI	Milano, Italy
ANTONIO	CURTI	Bologna, Italy
MICHELE	DEL VECCHIO	Milano, Italy
ENRICO	DERENZINI	Milano, Italy
MASSIMO	DI NICOLA	Milano, Italy
FRANCESCO	DI RAIMONDO	Catania, Italy
HERMANN	EINSELE	Würzburg, Germany
ROBERTO	FOA'	Roma, Italy
GIANLUCA	GAIDANO	Novara, Italy
MARIELLA	GRASSO	Cuneo, Italy
GIORGIO G.	INGHIRAMI	New York, USA
LARRY	KWAK	Duarte, USA
MARCO	LADETTO	Alessandria, Italy
ROBERTO M.	LEMOLI	Genova, Italy
MASSIMO	MASSAIA	Cuneo-Torino, Italy
DANIELE	MATTEI	Cuneo, Italy
FRANCESCO	MAURA	Miami, USA
NICOLA	MORDINI	Cuneo, Italy
LUIGI	NALDINI	Milano, Italy
SATTVA S.	NEELAPU	Houston, USA
CRISTINA	PAPAYANNIDIS	Bologna, Italy
ALESSANDRO	RAMBALDI	Bergamo, Italy
DAVIDE	RAPEZZI	Cuneo, Italy
ANNA	RUBINO	Cuneo, Italy
MARCO	RUELLA	Philadelphia, USA
CHIARA	RUSCONI	Milano, Italy

DOMENICO	RUSSO	Brescia, Italy
ELISA	SCARSELLI	Roma, Italy
MARTINA	SEIFFERT	Heidelberg, Germany
ROBERTO	SORASIO	Cuneo, Italy
JULE	TAUBMANN	Erlangen, Germany
ALESSANDRA	TEDESCHI	Milano, Italy
SARAH	TETTAMANTI	Monza-MB, Italy
LIVIO	TRANCHIDA	Cuneo, Italy
LUCA A.E.	VAGO	Milano, Italy
UMBERTO	VITOLO	Candiolo-TO, Italy

13:45 - 14:00 Welcome
M. Massaia, L. Tranchida, A. Rubino

14:00 - 16:00 **SESSION I**
Immunotherapy and targeted therapy in lymphoid malignancies I
Chairmen: C. Castellino, U. Vitolo

14:00 - 14:20 News and views in indolent lymphomas
E. Derenzini

14:20 - 14:30 Discussion

14:30 - 14:50 News and views in aggressive lymphomas
C. Carlo-Stella

14:50 - 15:00 Discussion

15:00 - 15:20 News and views in Hodgkin lymphoma
C. Rusconi

15:20 - 15:30 Discussion

15:30 - 15:50 News and views in acute lymphoblastic leukemia
A. Rambaldi

15:50 - 16:00 Discussion

16:00 - 16:30 *Coffee break*

16:30 - 18:30 **SESSION II**
Immunotherapy and targeted therapy in lymphoid malignancies II
Chairmen: F. Di Raimondo, M. Grasso

16:30 - 16:50 News and views in chronic lymphocytic leukemia and Waldenström disease

A. Tedeschi

16:50 - 17:00 Discussion

17:00 - 17:20 Tumor-host interactions as determinants of immunotherapy responses in CLL

M. Seiffert

17:20 - 17:30 Discussion

17:30 - 17:50 Bispecific antibodies and CAR-T in multiple myeloma
H. Einsele

17:50 - 18:00 Discussion

18:00 - 18:20 Genomic and immune predictors of immunotherapy responses in myeloma

F. Maura

18:20 - 18:30 Discussion

09:30 - 11:00

SESSION III

Immunotherapy and targeted therapy in myeloid malignancies

Chairmen: R.M. Lemoli, D. Mattei

09:30 - 09:50

Current and future approaches: from AML to BPDCN

C. Papayannidis

09:50 - 10:00

Discussion

10:00 - 10:20

CAR-T in AML: ready for prime time?

S. Tettamanti

10:20 - 10:30

Discussion

10:30 - 10:50

Immune dysregulation and driver mutations in myeloid malignancies

A. Curti

10:50 - 11:00

Discussion

11:00 - 11:30

Coffee break

11:30 - 13:00

SESSION IV

Expanding CAR-T cell applications and efficacy

Chairmen: C. Botta, D. Rapezzi

11:30 - 11:50

CAR-T SIE: state of the art

P. Corradini

11:50 - 12:00

Discussion

12:00 - 12:20

Mechanisms of CAR-T resistance

M. Ruella

12:20 - 12:30

Discussion

12:30 - 12:50

CAR-T cell therapy in autoimmune diseases

J. Taubmann

12:50 - 13:00

Discussion

13:00 - 14:00

Lunch

14:00 - 15:30

SESSION V

Exploring innovative cell-therapy approaches I

Chairmen: R. Foà, M. Ladetto

14:00 - 14:20

Editing of tumor microenvironment with targeted cell and gene therapy

L. Naldini

14:20 - 14:30

Discussion

14:30 - 14:50

Allogeneic CAR-T cell therapy: mechanisms of expansion and rejection

S.S. Neelapu

14:50 - 15:00

Discussion

15:00 - 15:20

Clinical results on decentrally manufactured CD19 CAR-T cells

M. Massaia

15:20 - 15:30

Discussion

15:30 - 16:00

Coffee break

16:00 - 18:00

SESSION VI

Exploring innovative cell-therapy approaches II

Chairmen: D. Cilloni, G. Gaidano

16:00 - 16:20

NKT as alternative TCR/CAR-T cell platform

G. Casorati

16:20 - 16:30

Discussion

16:30 - 16:50

Humanized mouse models as a predictive platform for adaptive immunotherapy

G.G. Inghirami

16:50 - 17:00

Discussion

17:00 - 17:20

Personalized oncolytic virotherapy

V. Cerullo

17:20 - 17:30

Discussion

17:30 - 17:50

An immune portfolio for ALK tumors: from vaccine to cellular immunotherapies

R. Chiarle

17:50 - 18:00

Discussion

09:30 - 11:00

SESSION VII

Immunological hints from solid tumors

Chairmen: D. Russo, R. Sorasio

09:30 - 09:50

Discovery of new targets for CAR-T cells in solid tumors

M. Di Nicola

09:50 - 10:00

Discussion

10:00 - 10:20

Neoantigens based vaccines in cancer prevention

E. Scarselli

10:20 - 10:30

Discussion

10:30 - 10:50

Individualized neoantigenic therapy in melanoma

M. Del Vecchio

10:50 - 11:00

Discussion

11:00 - 11:30

Coffee break

11:30 - 13:00

SESSION VIII

Personalized immunotherapy: from allotransplant to targeted therapy

Chairmen: B. Bruno, N. Mordini

11:30 - 11:50

Allotransplant state of the art

F. Ciceri

11:50 - 12:00

Discussion

12:00 - 12:20

Mechanisms of relapse: differences and similarities with CAR-T cells

L.A.E. Vago

12:20 - 12:30

Discussion

12:30 - 12:50

Towards a personalized approach to immune therapies for cancer: one drug, one patient

L. Kwak

12:50 - 13:00

Discussion

13:00 - 13:10

Goodbyes and meeting close

M. Massaia

With an unrestricted educational grant of

Johnson & Johnson

 NOVARTIS

| abbvie

AstraZeneca 

 BeiGene

Lilly

Galápagos

 GILEAD |  Kite

 Pfizer
Oncology

sanofi

 sobi
rare strength

GENERAL INFORMATION

MEETING VENUE

Spazio Incontri Fondazione CRC
Via Roma, 15
12100 Cuneo - Italy

REGISTRATION

Registration is free and available at www.ercongressi.it
in the section "I nostri congressi/2024"

OFFICIAL LANGUAGE

English. No simultaneous translation is provided.

CME

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi Srl - ID 828 - 421934
- N. 9,1 CME for Physicians (disciplines: pathologic anatomy, hematology, infectious diseases, internal medicine, transfusion medicine, oncology, clinical pathology (chemical analysis laboratory and microbiology), radiotherapy), Chemists (other sector chemist, SSN public chemist, territorial chemist), Biologists, Biomedical laboratory health technician, Nurses
- Educational Objective: linee guida-protocolli-procedure

SCIENTIFIC SECRETARIAT

Massimo Massaia

SC Ematologia - AO S. Croce e Carle
Via Michele Coppino 26, 12100 Cuneo, Italy
Laboratorio di Immunologia dei Tumori del
Sangue (LITS)
Centro Interdipartimentale di Ricerca
in Biologia Molecolare (CIRBM)
Università degli Studi di Torino

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it